8-K: ATAI Life Sciences Secures $50 Million Financing and Reports Positive Phase 2b Results for BPL-003 in Treatment-Resistant Depression

ATAI Life Sciences N.V. announced a $50 million private placement financing and the achievement of primary and key secondary endpoints in Beckley Psytech's Phase 2b clinical trial for BPL-003 in treatment-resistant depression, paving the way for a strategic combination.

Summary

• ATAI Life Sciences N.V. entered into subscription agreements on July 1, 2025, for a private placement (PIPE Financing) to raise approximately $50 million in gross proceeds.
• The PIPE Financing involves the purchase of 18,264,840 common shares at $2.19 per share and a pre-funded warrant to purchase 4,566,210 common shares at an exercise price of $0.01, with a purchase price of $2.18 per underlying share.
• Key investors in the PIPE Financing include Ferring Ventures S.A. and Apeiron Investment Group Ltd., the family office of Christian Angermayer, Co-Founder and Chairman of ATAI, along with other healthcare-focused institutional investors like Ally Bridge Group and ADAR1.
• Proceeds from the PIPE Financing are earmarked for general corporate purposes, including working capital and advancing the clinical development of product candidates and programs.
• Following the consummation of the PIPE Financing, ATAI estimates its cash, short-term securities, and public equity holdings will be sufficient to fund operating expenses into the second half of 2027.
• Beckley Psytech, a private clinical-stage biopharmaceutical company, publicly announced positive topline findings from the core part of its Phase 2b blinded clinical study of BPL-003 in 193 patients with moderate-to-severe treatment-resistant depression (TRD).
• A single 12 mg dose of BPL-003 resulted in a mean reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score of 11.1 from baseline compared to 5.8 in the 0.3 mg comparator arm (p=0.0038) at Day 29.
• An 8 mg dose of BPL-003 also showed a mean MADRS reduction of 12.1 from baseline (p=0.0025) at Day 29, demonstrating comparable efficacy to the 12 mg dose.
• Efficacy results were statistically significant in both active arms from as early as Day 2, with mean MADRS reductions of 8.8 in the 8 mg group and 8.9 in the 12 mg group.
• A durable effect was observed for both doses, with the 8 mg group showing a mean reduction of 10.8 points from baseline at Day 57 and the 12 mg group showing a mean reduction of 10.2 points from baseline compared to the 0.3 mg group (5.2 point reduction).
• BPL-003 was generally well-tolerated, with over 99% of adverse events reported as mild or moderate, and no drug-related serious adverse events or suicide-related safety signals.
• The majority of patients were deemed ready for discharge at 90 minutes post-dose, suggesting BPL-003 could fit within a 2-hour in-clinic treatment paradigm.
• The positive Phase 2b results for BPL-003 met the pre-agreed success criteria for the proposed strategic combination between ATAI and Beckley Psytech, which is now expected to progress to ATAI shareholder approval stage.
• The acquisition of Beckley Psytech, previously announced on June 2, 2025, involves ATAI issuing 105,044,902 common shares to Beckley Psytech shareholders for the remaining shares not already owned by ATAI.
• The closing of the PIPE Financing is not conditioned on the closing of the Beckley Psytech acquisition, and PIPE proceeds will not be used to finance the acquisition.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the successful achievement of primary and secondary endpoints in a significant Phase 2b clinical trial for a key product candidate (BPL-003), coupled with a substantial capital raise that extends the company's financial runway. The strategic acquisition of Beckley Psytech further strengthens the company's pipeline and market position in a growing therapeutic area. No significant negative or concerning details were disclosed.

Positives

• BPL-003 Phase 2b study met its primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in depressive symptoms.
• BPL-003 showed rapid antidepressant effects, with significant improvements observed as early as Day 2.
• The antidepressant effects of BPL-003 were durable, maintained out to Week 8 (Day 57) after a single dose.
• BPL-003 was generally well-tolerated, with over 99% of adverse events being mild or moderate and no drug-related serious adverse events or suicide-related safety signals.
• The short in-clinic time (majority of patients ready for discharge at 90 minutes post-dose) supports BPL-003's potential integration into existing interventional psychiatry treatment paradigms.
• The successful Phase 2b results support the selection of the 8 mg dose for advancement into Phase 3 clinical studies.
• The positive clinical data met the pre-agreed success criteria for the strategic combination with Beckley Psytech, which is expected to create a global leader in short-time in-clinic psychedelic-based mental health therapies.
• The $50 million private placement financing significantly strengthens ATAI's financial position, extending its cash runway into the second half of 2027.
• Participation of existing and new healthcare-focused institutional investors, including Ferring Ventures S.A. and Ally Bridge Group, indicates strong investor confidence.

Negatives

• No specific negatives were highlighted in the document regarding the financial performance or clinical trial outcomes; the tone is overwhelmingly positive.

Risks

• The PIPE Financing is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) related to Christian Angermayer's filing.
• The Company's estimate of cash runway into the second half of 2027 is based on assumptions that may prove incorrect, and available capital resources could be used sooner than expected.
• The proposed acquisition of Beckley Psytech may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• There is a risk of failure to realize the anticipated benefits of the proposed acquisition, including strategic value and financial synergies.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the share purchase agreement for the acquisition.
• The announcement or pendency of the proposed acquisition could affect ATAI's ability to retain and hire key personnel, or its operating results and business generally.
• Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, as described in the 'Risk Factors' section of the most recent Annual Report on Form 10-K.
• Clinical development of product candidates is inherently uncertain, and the potential, success, cost, and timing of development may vary.

Future Outlook

ATAI Life Sciences expects the PIPE Financing to close in the third quarter of 2025, extending its cash runway into the second half of 2027. The strategic combination with Beckley Psytech is anticipated to close in the second half of 2025, pending ATAI shareholder approval. Following the positive Phase 2b results for BPL-003, ATAI and Beckley Psytech plan to engage with regulatory bodies, including the U.S. FDA, in the coming months to prepare for Phase 3 clinical studies, with a clear Phase 3 plan targeted for early 2026. Data from the BPL-003 open-label extension study is expected in Q3 2025, providing further insights into repeat dosing safety, tolerability, and durability.

Management Comments

• Cosmo Feilding Mellen, CEO and Co-Founder of Beckley Psytech, stated: 'The achievement of our primary and secondary endpoints in this study represents an important milestone in the development of BPL-003 and reinforces its potential to be a viable treatment option for patients and healthcare systems. We are particularly encouraged that a single 8 mg or 12 mg dose of BPL-003 showed rapid and durable efficacy results, favourable tolerability and a short time in-clinic, giving us important flexibility in optimising the design of future trials.'
• Dr. David Feifel, Professor Emeritus of Psychiatry at the University of California, San Diego, commented: 'What stands out in these results is that a single administration of BPL-003 in patients with treatment-resistant depression was generally well tolerated and produced a robust antidepressant effect that emerged rapidly and was solidly sustained for at least two months. Notably, the acute psychedelic effects were shorter than with most other psychedelics studied clinically, suggesting potential for a quicker functional recovery for patients and a reduced need for prolonged monitoring. If a treatment with this profile were available today, it would immediately become my treatment of choice for TRD.'
• Srinivas Rao, CEO and Co-Founder of ATAI, said: 'These findings strengthen our confidence in the potential of BPL-003 to be a transformative psychedelic therapy, offering rapid and durable antidepressive effects with minimal in-clinic time for patients with treatment-resistant depression. We look forward to engaging with the regulators later this year to advance this innovative treatment into Phase 3 clinical development.'
• Christian Angermayer, Co-Founder and Chairman of ATAI, commented: 'With this financing, atai is well-positioned to accelerate its efforts and achieve its goal of delivering new therapeutic options for individuals facing serious mental health challenges. We are confident that these trial results will support a robust discussion with the FDA and allow us have a clear Phase 3 plan early in 2026. I am especially grateful for the repeated support of Ferring Ventures. Their deep understanding of commercialization, market dynamics, and how to build and run effective sales teams is invaluable for atai as it prepares to transform from a clinical-stage biotech into a fully integrated commercial company over time.'
• Jean-Frederic Paulsen, Chairman, Ferring Ventures S.A., added: 'Psychedelics have demonstrated remarkable potential as a transformative class of treatments for a range of mental health conditions. atai has consistently led innovation and progress in this space, and I am pleased to expand our investment to support atai in pioneering the next generation of mental health treatments.'

Industry Context

The announcement positions ATAI Life Sciences and the soon-to-be-acquired Beckley Psytech as a potential global leader in short-time in-clinic psychedelic-based mental health therapies. The positive Phase 2b results for BPL-003, particularly its rapid and durable effects with a short in-clinic time, directly address a significant unmet need in treatment-resistant depression. The strategy aims to leverage the established interventional psychiatry treatment paradigm, exemplified by Johnson & Johnson's Spravato, which has demonstrated commercial success with its 2-hour in-clinic model. This approach seeks to overcome scalability limitations often associated with longer-duration psychedelic therapies, potentially improving provider burden and payer receptivity, thereby accelerating the integration of psychedelic-based treatments into mainstream healthcare.

Comparison to Industry Standards

• BPL-003's average time to meet readiness for discharge criteria was within two hours of dosing, with the majority of patients ready at 90 minutes post-dose. This aligns with the existing 2-hour in-clinic interventional psychiatry treatment paradigm successfully established by Spravato (esketamine).
• A single dose of BPL-003 demonstrated comparable MADRS response to published results from a twice-weekly Spravato monotherapy dosing regimen, suggesting a potentially reduced dosing frequency for BPL-003.
• Spravato achieved global annual sales of $1.077 billion in 2024 and is projected to reach $3 billion to $3.5 billion in annual sales by 2028, indicating a significant market opportunity for treatments fitting this paradigm.
• BPL-003 offers potential advantages over Spravato with a longer duration of effect from fewer required dosing sessions, which could reduce patient burden compared to Spravato's twice-weekly induction phase and weekly/bi-weekly maintenance.
• Unlike longer-duration psychedelics such as psilocybin, MDMA, or LSD, which may require 6-12 hours of clinic time and extensive therapist involvement, BPL-003's short in-clinic time (approximately 2 hours) enhances its commercial scalability and potential for broader adoption within healthcare systems.

Related Party Transactions

• Apeiron Investment Group Ltd., the family office of Christian Angermayer (Co-Founder and Chairman of ATAI), participated in the PIPE Financing.
• Christian Angermayer is expected to make a filing pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with Apeiron's investment in the PIPE Financing, which is a closing condition for the PIPE.

Stakeholder Impact

• **Shareholders:** The PIPE financing and positive clinical trial results are likely to be viewed positively, potentially increasing share price. The acquisition of Beckley Psytech aims to create a global leader, potentially enhancing long-term shareholder value. Existing shareholders will experience dilution from the issuance of new shares for both the PIPE and the acquisition.
• **Patients:** The positive Phase 2b results for BPL-003 offer significant hope for a new, rapid-acting, and durable treatment option for treatment-resistant depression, addressing a high unmet medical need.
• **Employees:** The strategic combination with Beckley Psytech is expected to create a larger, more integrated company, potentially offering new opportunities but also potential for organizational changes.
• **Creditors:** The $50 million capital raise strengthens the company's financial position and extends its cash runway, reducing immediate financial risk.
• **Suppliers/Partners:** Continued clinical development and potential commercialization of BPL-003 will likely lead to increased engagement with suppliers and partners in the biopharmaceutical and healthcare sectors.

Next Steps

• Engage with the U.S. Food and Drug Administration (FDA) and other applicable regulatory agencies regarding the Phase 3 trial design for BPL-003 in patients with treatment-resistant depression in the coming months.
• Progress the strategic combination between ATAI Life Sciences and Beckley Psytech to the ATAI shareholder approval stage.
• Close the PIPE Financing, expected in the third quarter of 2025, subject to customary closing conditions including HSR Act clearance.
• Share additional data from the BPL-003 core study through future publications and medical meetings.
• Anticipate topline data from the 8-week open-label extension (OLE) stage of the BPL-003 study in the third quarter of 2025.
• Anticipate topline data from the Phase 2a open-label cohort investigating a 2-dose induction model for BPL-003 (n=12).
• Request an FDA End of Phase 2 meeting for BPL-003.
• File a registration statement on Form S-4, which will include a proxy statement, in connection with the proposed acquisition of Beckley Psytech Limited.
• File a registration statement with the SEC registering the resale of the common shares issued in the private placement and the common shares issuable upon exercise of the Pre-Funded Warrants.

Key Dates

Recommendation

Keywords

ATAI Life Sciences, Beckley Psytech, BPL-003, Treatment-Resistant Depression, TRD, Psychedelic Therapy, 5-MeO-DMT, Clinical Trial, Phase 2b, Private Placement, PIPE Financing, Capital Raise, Acquisition, Biopharmaceutical, Mental Health, Drug Development, SEC Filing, Form 8-K, Nasdaq